JP2023528450A5 - - Google Patents
Info
- Publication number
- JP2023528450A5 JP2023528450A5 JP2022574390A JP2022574390A JP2023528450A5 JP 2023528450 A5 JP2023528450 A5 JP 2023528450A5 JP 2022574390 A JP2022574390 A JP 2022574390A JP 2022574390 A JP2022574390 A JP 2022574390A JP 2023528450 A5 JP2023528450 A5 JP 2023528450A5
- Authority
- JP
- Japan
- Prior art keywords
- peaks
- approximately
- theta
- degrees
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063034900P | 2020-06-04 | 2020-06-04 | |
| US63/034,900 | 2020-06-04 | ||
| PCT/US2021/035796 WO2021247934A1 (en) | 2020-06-04 | 2021-06-03 | Forms and compositions of a beta adrenergic agonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023528450A JP2023528450A (ja) | 2023-07-04 |
| JP2023528450A5 true JP2023528450A5 (cg-RX-API-DMAC7.html) | 2024-05-29 |
| JP7734700B2 JP7734700B2 (ja) | 2025-09-05 |
Family
ID=78829944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574390A Active JP7734700B2 (ja) | 2020-06-04 | 2021-06-03 | ベータアドレナリンアゴニストの形態及び組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230219892A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4161496A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7734700B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230021075A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115989019B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021282582A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3179993A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022015165A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021247934A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11607395B2 (en) | 2019-12-18 | 2023-03-21 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| JP2023541379A (ja) * | 2020-09-01 | 2023-10-02 | キュラセン セラピューティクス インコーポレイテッド | 神経系の疾患及び障害を改善するための組成物及び方法 |
| US12616667B2 (en) | 2021-11-15 | 2026-05-05 | Curasen Therapeutics, Inc. | Compositions and methods for improving neurological diseases and disorders |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
| CN120583945A (zh) | 2023-01-20 | 2025-09-02 | 阿托基公司 | 用于治疗或预防肌肉消耗的β2-肾上腺素能受体激动剂 |
| GB202302225D0 (en) | 2023-02-16 | 2023-04-05 | Atrogi Ab | New medical uses |
| GB202303229D0 (en) | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| GB202403169D0 (en) | 2024-03-05 | 2024-04-17 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019578A (en) * | 1987-11-27 | 1991-05-28 | Merck & Co., Inc. | β-adrenergic agonists |
| WO2003072573A1 (en) * | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
| WO2011133226A2 (en) | 2010-04-22 | 2011-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same |
| BR112013012994A2 (pt) * | 2010-11-24 | 2016-09-13 | Lithera Inc | formulações monoterapêuticas de beta-agonista de longa duração, lipofílicas e seletivas e métodos para o tratamento cosmético da adiposidade e saliência de contorno |
| US9320724B2 (en) | 2013-02-13 | 2016-04-26 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor |
| US9889087B2 (en) | 2014-06-10 | 2018-02-13 | The Board Of Trustees Of The Leland Stanford Junior University | Intranasal delivery of β2-adrenergic receptor agonists for improving cognition in humans with down syndrome and compositions therefor |
| BR112018073227A2 (pt) * | 2016-05-13 | 2019-02-19 | The Board Of Trustees Of The Leland Stanford Junior University | compostos moduladores do receptor adrenérgico e métodos de uso do mesmo |
| WO2018169742A1 (en) * | 2017-03-14 | 2018-09-20 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibtor |
| GB201714745D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| EP3806957A4 (en) * | 2018-06-14 | 2022-03-16 | Curasen Therapeutics, Inc. | METHODS OF DIAGNOSIS, MONITORING AND TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS |
| US10947196B2 (en) * | 2019-03-27 | 2021-03-16 | Curasen Therapeutics, Inc. | Beta adrenergic agonist and methods of using the same |
-
2021
- 2021-06-03 JP JP2022574390A patent/JP7734700B2/ja active Active
- 2021-06-03 MX MX2022015165A patent/MX2022015165A/es unknown
- 2021-06-03 WO PCT/US2021/035796 patent/WO2021247934A1/en not_active Ceased
- 2021-06-03 AU AU2021282582A patent/AU2021282582A1/en active Pending
- 2021-06-03 EP EP21818923.1A patent/EP4161496A4/en active Pending
- 2021-06-03 US US18/007,726 patent/US20230219892A1/en active Pending
- 2021-06-03 CN CN202180048013.4A patent/CN115989019B/zh active Active
- 2021-06-03 KR KR1020237000115A patent/KR20230021075A/ko active Pending
- 2021-06-03 CA CA3179993A patent/CA3179993A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018349279B2 (en) | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use | |
| JP5269349B2 (ja) | ベンゾピラン−2−オール誘導体の製造のための方法 | |
| JP2011513485A5 (cg-RX-API-DMAC7.html) | ||
| JP5377285B2 (ja) | キラルアミドおよびキラルアミンの調製 | |
| AU2008243132B2 (en) | New crystalline form VI of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| JP4575337B2 (ja) | アゴメラチンの新規な結晶形態v、その製造方法、およびそれを含有する薬学的組成物 | |
| EP2049464A1 (en) | Preparation of 3-ý(1r,2r)-3-(dimethylamino)-1ethyl-2-methylpropyl¨phenol | |
| JP2005503386A5 (cg-RX-API-DMAC7.html) | ||
| HU228436B1 (en) | 6-fluorobicyclo[3.1.0]hexane derivatives | |
| JPH09504024A (ja) | 置換2,5−ジアミノ−3−ヒドロキシヘキサンの製造方法 | |
| JP2015531403A (ja) | ベンズアミド化合物の合成に有用な化合物 | |
| TWI725098B (zh) | 藉由使用極性非質子性溶劑掌性解析n-[4-(1-胺基乙基)-苯基]-磺醯胺衍生物之方法 | |
| CN1216033C (zh) | 亚环己基胺的顺式选择性催化氢化方法 | |
| CN1288153C (zh) | 2-氨基-4-吡啶基甲基-二氢噻唑衍生物作为诱导型no-合酶抑制剂的用途 | |
| WO2014111836A1 (en) | Process for preparation of fingolimod and its salts | |
| JP2025069143A (ja) | tert-ブチル(S)-2-((2S,3R)-1-アミノ-3-ヒドロキシ-1-オキソブタン-2-イル)-1-オキソ-2,5-ジアザスピロ[3.4]オクタン-5-カルボキシレートの固体形態およびそれらを調製する方法 | |
| HU227114B1 (en) | (1r, 2s, 4r)-(-)-2-[n,n-(dimethylamino-ethoxy)]-2-phenyl-1,7,7-trimethyl-bicyclo[2.2.1]heptane of high purity and pharmaceutically acceptable acid addition salts thereof, process for preparation of them and medicaments containing the same | |
| CN107445845A (zh) | 一种合成氯法齐明关键中间体n‑(4‑氯苯基)‑1,2‑苯二胺的方法 | |
| AU2016327159A1 (en) | The process of preparing indoline compounds and a novel indoline salt | |
| WO2005000790A1 (ja) | 2-アミノビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸誘導体 | |
| JP2022539342A5 (cg-RX-API-DMAC7.html) | ||
| JPH08509979A (ja) | 光学活性な3−(1−(アルキルアミノ))アルキルピロリジン類 | |
| WO2018193482A1 (en) | Improved method for the synthesis of 1,2-ethanediamine, n, n'-bis(2-aminoethyl)-dihydrochloride(trientine dihydrochloride) | |
| CA2484981A1 (en) | 1,3,5-triazine derivatives as ligands for human adenosine-a3 receptors | |
| WO2009072062A2 (en) | Novel derivatives of dihydroxypyrrolidine as anti-cancer compounds |